| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Director
2 companies
Avraham Gabay is Chief Financial Officer at ORMP and has filed Form 4s across 2 companies. Avraham Gabay's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.6M at current prices.
The biggest single holding is ORMP (~$3.6M) as Chief Financial Officer. The ORMP filings lean toward selling, a net 93,360 shares.
Avraham Gabay has 14 Form 4 filings on record from June 2019 to October 2026, across 2 companies: Chief Financial Officer at Oramed Pharmaceuticals (ORMP), 2019–2026; Director at Lifeward (LFWD), 2026.
The 18 reported transactions were 10 stock awards, 4 option or other derivative awards, 2 open-market sales and 1 option exercise, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $421K.
The largest open-market sale was 73,360 shares of ORMP at an average $4.51 on July 1, 2026, about $331K.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.